Widdop lab publications

Selected highlight publications

1.  Young ON, Bourke JE, Widdop RE. 2023. Catch your breath: The protective role of the angiotensin AT2 receptor for the treatment of idiopathic pulmonary fibrosis. Biochem Pharmacol. 217:115839.

2.  Steckelings UM, Widdop RE, Sturrock ED, Lubbe L, Hussain T, Kaschina E, Unger T, Hallberg A, Carey RM, Sumners C. 2022. The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target. Pharmacol Rev. 74:1051-1135.

3.  Commentary on Prof Widdop’s long-standing work in the AT2R field:
Sumners C, Silva IMS, Steckelings UM. 2022. Commentary: Angiotensin receptors - Affinity and Beyond. Clinical Science 136: 799–802.

4. Chassagnon IR, McCarthy CA, Chin YK, Pineda SS, Keramidas A, Mobli M, Pham V, De Silva TM, Lynch JW, Widdop RE, Rash LD, King GF. 2017. Potent neuroprotection after stroke afforded by a double-knot spider-venom peptide that inhibits acid-sensing ion channel 1a. Proc Natl Acad Sci 114:3750-3755.

5. Del Borgo M, Wang Y, Bosnyak S, Khan M, Walters P, Spizzo I, Perlmutter P, Hilliard L, Denton K, Aguilar MI, Widdop RE, Jones ES. 2015. β-Pro7Ang III is a novel highly selective angiotensin II type 2 receptor (AT2R) agonist, which acts as a vasodepressor agent via the AT2R in conscious spontaneously hypertensive rats. Clin Sci 129(6):505-13.

6. Chow BS, Kocan M, Bosnyak S, Sarwar M, Wigg B, Jones ES, Widdop RE, Summers RJ, Bathgate RA, Hewitson TD, Samuel CS. 2014. Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis. Kidney Int 86:75-85.

7. Gaspari T, Liu H, Welungoda I, Hu Y, Widdop RE, Knudsen LB, Simpson RW, Dear AE. 2011. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model. Diab Vasc Dis Res 8, 117-24.

Additional publications

A full list of Widdop Lab publications can be viewed on PubMed.